Larsson, B.A.M.
Johansson, L.
Mellström, D.
Johansson, H.
Axelsson, K.F.
Harvey, N.
Vandenput, L.
McCloskey, E.
Liu, E.
Sundh, D.
Kanis, J.A.
Lorentzon, M. http://orcid.org/0000-0003-0749-1431
Funding for this research was provided by:
VetenskapsrÄdet
Sahlgrenska Universitetssjukhuset
IngaBritt och Arne Lundbergs Forskningsstiftelse
Article History
Received: 20 April 2021
Accepted: 15 June 2021
First Online: 8 September 2021
Declarations
:
: Professor Lorentzon has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. N. Harvey has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health, and Internis Pharma outside the scope of the submitted work. K. Axelsson has received lecture fees from Lilly, Meda/Mylan, and Amgen. E McCloskey has received consultancy, research funding, lecture fees, and/or honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, ObsEva, Synexus, and UCB outside the scope of this work. All other authors have no conflicts of interest.